| Old Articles: <Older 5981-5990 Newer> |
|---|
 |
The Motley Fool
October 30, 2009
Brian Orelli |
Of One-Time Gains and Pipelines AstraZeneca's earnings report illustrates the nature of polar opposites with one-time gains and new drugs. One is to be largely ignored, while the other will drive the drugmaker's future.   |
The Motley Fool
October 30, 2009
Brian Orelli |
World's Scariest Stocks: Pfizer For Pfizer, the big, scary unknown comes from whether it can integrate its recent acquisition of Wyeth. |
BusinessWeek
October 29, 2009
Arlene Weintraub |
Testosterone Is Sure Looking Virile Despite legal setbacks and FDA delays, youth-crazed boomers are making testosterone a billion-dollar industry. |
InternetNews
October 29, 2009 |
California Medicaid Members' Data Exposed Thousands of Orange County patients' on high alert after CDs go missing. |
The Motley Fool
October 29, 2009
Brian Orelli |
Expressing Itself Nicely A nice quarter for Express Scripts. |
The Motley Fool
October 29, 2009
Robert Steyer |
Pharma Researchers Need a Cure As the industry changes, Pharmaceutical Product Development and Parexel International struggle. |
The Motley Fool
October 29, 2009
Brian Orelli |
Small and Volatile, but Not for Long BioMarin is growing. |
The Motley Fool
October 28, 2009
Brian Orelli |
Saved by Emerging Markets. Sort Of. GlaxoSmithKline's top line looks good, but the bottom is what counts. |
The Motley Fool
October 27, 2009
Brian Orelli |
Pfizer's and Merck's Loss Is These Companies' Gain Are Pfizer and Merck too busy integrating now to take advantage of additional acquisitions? |
The Motley Fool
October 27, 2009
Brian Orelli |
Small Market, Small Acquisition, Still a Good Move BioMarin does everything small. |
| <Older 5981-5990 Newer> Return to current articles. |
